MedPath

Double treatment with Glycopyrronium and Indacaterol versus single treatment with Glycopyrronium in treatment of lung disease

Phase 4
Conditions
pulmonary emphysema
pulmonary disease
chronic obstructive
C08.381.495.389.750
C08.381.495.389
Registration Number
RBR-7k576j
Lead Sponsor
Hospital de Clínicas da Universidade Federal do Paraná
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Patients (men and women) with COPD confirmed by spirometry. The diagnosis of the disease will be made by performing spirometry that will confirm the obstruction to the airflow through the result of the relation between forced expiratory volume in the first second (FEV1) and forced vital capacity of less than seventy per cent after use of inhaled bronchodilator. The patient must have stable disease. No need for hospitalization in the thirty days prior to the evaluation. Preserved neurocognitive functions. Be an adult and agree to participate in the study.

Exclusion Criteria

Patients with respiratory tract infection or who have been hospitalized for an exacerbation in the last month.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br>The primary endpoint is a greater benefit and therapeutic efficacy when adding a second bronchodilator in the treatment of chronic obstructive pulmonary disease (COPD) in patients with moderate COPD.<br>For this the main outcome will be analyzed through spirometry. The variable analyzed for this is the forced expiratory volume in the first minute (FEV1) pre-bronchodilatation, as seen by the spirometry examination. It is a variable of drug effectiveness.<br>In summary: pre-bronchodilation FEV1 is expected to increase after treatment with double therapy when compared to treatment with monotherapy. This increase should be statistically significant.
Secondary Outcome Measures
NameTimeMethod
Secondary outcomes are not expected
© Copyright 2025. All Rights Reserved by MedPath